1. Home
  2. ACOG vs INO Comparison

ACOG vs INO Comparison

Compare ACOG & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$7.00

Market Cap

110.4M

Sector

N/A

ML Signal

HOLD

Logo Inovio Pharmaceuticals Inc.

INO

Inovio Pharmaceuticals Inc.

HOLD

Current Price

$1.14

Market Cap

90.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACOG
INO
Founded
2000
1979
Country
Canada
United States
Employees
57
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.4M
90.5M
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
ACOG
INO
Price
$7.00
$1.14
Analyst Decision
Strong Buy
Buy
Analyst Count
2
4
Target Price
$16.00
$6.75
AVG Volume (30 Days)
30.0K
1.6M
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.18
EPS
N/A
N/A
Revenue
N/A
$42,220,086.00
Revenue This Year
$139.22
$20,156.19
Revenue Next Year
$134.48
$421.95
P/E Ratio
N/A
N/A
Revenue Growth
N/A
19.37
52 Week Low
$4.50
$1.03
52 Week High
$10.88
$2.86

Technical Indicators

Market Signals
Indicator
ACOG
INO
Relative Strength Index (RSI) 68.32 41.74
Support Level $6.46 $1.03
Resistance Level $7.69 $1.23
Average True Range (ATR) 0.36 0.06
MACD 0.09 -0.00
Stochastic Oscillator 91.89 22.92

Price Performance

Historical Comparison
ACOG
INO

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

About INO Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

Share on Social Networks: